Coadministration of endothelial and smooth muscle progenitor cells enhances the efficiency of proangiogenic cell-based therapy
Coadministration of endothelial and smooth muscle progenitor cells enhances the efficiency of proangiogenic cell-based therapy
复制标题
DOI：
10.1161/circresaha.108.175083
复制
发表时间：
2008-09-26
影响因子：
20.1
通讯作者：
Tobelem, Gerard
中科院分区：
文献类型：
--
作者：
Foubert, Philippe;Matrone, Gianfranco;Tobelem, Gerard
基于细胞的治疗是一种有前途的方法，旨在增强缺血组织的新血管形成和功能。内皮细胞和平滑肌细胞之间的相互作用调节血管发育和重塑，并且是形成成熟和功能性血管网络所必需的。因此，我们评估了内皮祖细胞（EPC）和平滑肌祖细胞（SMPC）的共同给药是否可以提高细胞治疗的效率。在静脉注射或不静脉注射EPCs (0.5 x 10(6))、SMPCs (0.5 x 10(6)) 和EPCs+MPCs (0.25 x 10(6) + 0.25 x 10(6)) 治疗的无胸腺裸鼠中通过手术诱导单侧后肢缺血。与单独接受 EPC 或单独 SMPC 的动物相比，用 EPC+SMPC 治疗的小鼠的血管密度和足部灌注增加（P
Cell-based therapy is a promising approach designed to enhance neovascularization and function of ischemic tissues. Interaction between endothelial and smooth muscle cells regulates vessels development and remodeling and is required for the formation of a mature and functional vascular network. Therefore, we assessed whether coadministration of endothelial progenitor cells (EPCs) and smooth muscle progenitor cells (SMPCs) can increase the efficiency of cell therapy. Unilateral hindlimb ischemia was surgically induced in athymic nude mice treated with or without intravenous injection of EPCs (0.5 x 10(6)), SMPCs (0.5 x 10(6)) and EPCs+MPCs (0.25 x 10(6) + 0.25 x 10(6)). Vessel density and foot perfusion were increased in mice treated with EPCs+SMPCs compared to animals receiving EPCs alone or SMPCs alone (P